ArticleFrontiers in immunology2022
Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 10 citations in OpenAlex.
- The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.Nature aging · 2026Article
- Oxidative DNA Damage Is Associated with Immune Remodeling and Therapeutic Response in High-Grade Serous Ovarian Cancer.Cancers · 2026Article
- RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer.Cell reports · 2026Article
- Chemotherapy induces an IL1β-dependent neutrophil recruitment and activation that promote chemoresistance in metastatic ovarian cancer.Journal for immunotherapy of cancer · 2026Article
- Cross-assay RNA modeling reveals cancer biomarkers.bioRxiv : the preprint server for biology · 2026Article
- On the predictability of progression-free survival in ovarian cancer from NanoString gene expression data.bioRxiv : the preprint server for biology · 2026Article
- Cell-intrinsic and tumor microenvironmental determinants of platinum resistance in epithelial ovarian cancer.Discover oncology · 2026Review
- Association between HER2 expression, genomic characteristics, and tumor immune microenvironment dynamics in epithelial ovarian cancer.Frontiers in oncology · 2026Article
- Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets.Frontiers in immunology · 2026Review
- The silent spread: exploring diverse metastatic pathways in high-grade serous ovarian cancer.Frontiers in medicine · 2025Review
- NF-κB associated markers of prognosis in early and metastatic triple negative breast cancer.Breast cancer research : BCR · 2024Article
- Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer.Journal of ovarian research · 2024Article
- ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.Cell death & disease · 2024Article
- Enhanced amphiregulin exposure promotes modulation of the high grade serous ovarian cancer tumor immune microenvironment.Frontiers in pharmacology · 2024Article
- High Tumor-Infiltrating Lymphocyte Count Is Associated with Distinct Gene Expression Profile and Longer Patient Survival in Advanced Ovarian Cancer.International journal of molecular sciences · 2023Article
- Tumor Immune Microenvironment in Gynecologic Cancers.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high rate of ovarian cancer recurrence and chemoresistance necessitates further research into how chemotherapy affects the tumor immune microenvironment (TIME). While studies have shown that immune infiltrate increases following neoadjuvant (NACT) chemotherapy, there lacks a comprehensive understanding of chemotherapy-induced effects on immunotranscriptomics and cancer-related pathways and their relationship with immune infiltrate and patient responses. In this study, we performed NanoString nCounter
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.